natgillin/translations-raw huggingface dataset:
7 depotplastre 30 depotplastre 60 depotplastre 90 depotplastre 
7 transdermal patches 30 transdermal patches 60 transdermal patches 90 transdermal patches
- hvis du har nedsat leverfunktion. 
- if you have impaired liver function.
Gennemsnitsscore  SD p-værdi versus placebo ADCS-ADL 
Mean score  SD p-value versus placebo ADCS-ADL
Hvert depotplaster er forseglet i et brev. 
One transdermal patch is sealed in one pouch.
Studiet var designet til at sammenligne effekten af 13,3 mg/24 timer depotplaster med 9,5 mg/24 timer depotplaster i løbet af en 48-ugers dobbeltblindet behandlingsfase hos patienter med Alzheimers sygdom, som viste funktionel og kognitiv tilbagegang efter en indledende 24-48 ugers åben behandlingsfase med anvendelse af en vedligeholdelsesdosis på 9,5 mg/24 timer depotplaster. 
The study was designed to compare the efficacy of the 13.3 mg/24 h transdermal patch against the 9.5 mg/24 h transdermal patch during a 48-week double-blind treatment phase in Alzheimer's disease patients who demonstrated functional and cognitive decline after an initial 24-48 week openlabel treatment phase while on a maintenance dose of 9.5 mg/24 h transdermal patch.
• Pædiatrisk population: Der er ingen relevante indikationer for brug af Rivastigmine 3M Health Care Ltd. i den pædiatriske population til behandling af Alzheimers demens. 
Special populations - Paediatric population: There is no relevant use of Rivastigmine 3M Health Care Ltd. in the paediatric population in the treatment of Alzheimer's disease.
Enkelt-dosis inter-patientvariationerne i rivastigmins farmakokinetiske parametre (normaliseret til dosis/kg legemsvægt) var 43% (Cmax) og 49% (AUC0-24h) efter transdermal administration mod henholdsvis 74% og 103% efter den orale formulering. 
The single-dose inter-subject variability in rivastigmine pharmacokinetic parameters (normalised to dose/kg bodyweight) was 43% (Cmax) and 49% (AUC0-24h) after transdermal administration versus 74% and 103%, respectively, after the oral form.
Tabel 1 viser de bivirkninger, som blev rapporteret hos 854 patienter med Alzheimers demens behandlet med rivastigmin depotplastre med en varighed på 24-48 uger og fra post-marketing data i randomiserede, dobbeltblindede, placebo- og aktivkontrollerede kliniske studier. 
Table 1 displays the adverse reactions reported in 854 patients with Alzheimer's dementia treated in randomised, double-blind, placebo and active-controlled clinical studies with rivastigmine transdermal patches for a duration of 24-48 weeks and from post-marketing data.
Der må kun påføres ét plaster ad gangen (se pkt. 
Only one patch should be worn at a time (see section 4.9).
De mest almindeligt observerede svære symptomer med rivastigmin 9,5 mg/24 timer depotplastre var kløe (1,7%) og erytem (1,1%). 
The most commonly observed severe symptoms with rivastigmine 9.5 mg/24 h transdermal patches were pruritus (1.7%) and erythema (1.1%).
Hvis dette tåles godt, og kun efter minimum 6 måneders behandling med 9,5 mg/24 timer, kan den behandlende læge overveje at øge dosis til 13,3 mg/24 timer, hos patienter som har vist betydningsfuld kognitiv tilbagegang (fx nedgang i MMSE) og/eller funktionel nedgang (baseret på lægens bedømmelse) ved anvendelse af den anbefalede daglige vedligeholdelsesdosis på 9,5 mg/24 timer (se pkt 5.1). 
If well tolerated and only after a minimum of six months of treatment at 9.5 mg/24 h, the treating physician may consider increasing the dose to 13.3 mg/24 h in patients who have demonstrated a meaningful cognitive deterioration (e.g. decrease in the MMSE) and/or functional decline (based on physician judgement) while on the recommended daily effective dose of 9.5 mg/24 h (see section 5.1).
Et brev indeholder et depotplaster. 
One pouch contains one transdermal patch.
Hvis du ikke har brugt et depotplaster i 3 dage, skal du tale med din læge, før du bruger det næste. 
If you have not applied a patch for three days, do not apply the next one before you have talked to your doctor.
- Plasteret må ikke klippes i stykker. 
- The patch should not be cut into pieces.
Hvert depotplaster på 8,3 cm2 indeholder 14,33 mg rivastigmin. 
Each transdermal patch of 8.3 cm2 contains 14.33 mg of rivastigmine.
Rivastigmin er en kolinesterasehæmmer og kan forstærke virkningen af muskelrelaksantia af succinylkolintypen under anæstesi. 
As a cholinesterase inhibitor, rivastigmine may exaggerate the effects of succinylcholine-type muscle relaxants during anaesthesia.
Sjælden (kan forekomme hos op til 1 ud af 1.000 patienter) Fald 
Rare (may affect up to 1 in 1,000 people) - Falling
Hvert depotplaster på 4,15 cm2 indeholder 7,17 mg rivastigmin. 
Each transdermal patch of 4.15 cm2 contains 7.17 mg of rivastigmine.
• Huskekort til patienter 
• Patient reminder card
Hvis du har brugt for mange Rivastigmine 3M Health Care Ltd. depotplastre Hvis du kommer til at sætte mere end ét plaster på, skal du tage alle plastre af huden og informere din læge om, at du er kommet til at sætte flere plastre på. 
If you use more Rivastigmine 3M Health Care Ltd. than you should If you accidentally apply more than one patch, remove all the patches from your skin, then inform your doctor that you have accidentally applied more than one patch.
Hudreaktioner på applikationsstedet 
Skin application site reactions
Posologi 
Posology
Rivastigmine 3M Health Care Ltd. indeholder: - Aktivt stof: rivastigmin. 
What Rivastigmine 3M Health Care Ltd. contains - The active substance is rivastigmine.
På grund af øget biotilgængelighed hos disse patienter observeret med de orale formuleringer, bør anbefalingerne vedrørende titrering i henhold til individuel tolerance dog følges nøje, da patienter med klinisk signifikant nedsat leverfunktion kan opleve flere bivirkninger. 
However, due to increased exposure in these populations as observed with the oral forms, dosing recommendations to titrate according to individual tolerability should be closely followed as patients with clinically significant hepatic impairment might experience more adverse reactions.
Anamnese med reaktioner på applikationsstedet, der tyder på allergisk kontaktdermatitis af rivastigminplaster (se pkt. 
Previous history of application site reactions suggestive of allergic contact dermatitis with rivastigmine patch (see section 4.4).
Ikke kendt (hyppighed kan ikke beregnes ud fra tilgængelige data) Reaktioner på applikationsstedet, såsom blister eller betændelse i huden Symptomer på Parkinsons sygdom bliver værre- såsom rysten, stivhed og slæben Betændelse i bugspytkirtelen - symptomerne omfatter alvorlige smerter øverst i maven, ofte med kvalme eller opkastning Hurtig eller uregelmæssig hjerterytme (puls) 
Not known (frequency cannot be estimated from the available data) - Allergic reaction where the patch was used, such as blisters or inflamed skin - The signs of Parkinson's disease get worse - such as tremor, stiffness and shuffling - Inflammation of the pancreas - signs include serious upper stomach pain, often with feeling sick
Depotplasteret påføres én gang dagligt på ren, tør, hårløs intakt sund hud på ryg, overarm eller bryst på et sted, hvor stramt tøj ikke kan gnide mod plasteret. 
Transdermal patches should be applied once a day to clean, dry, hairless, intact healthy skin on the upper or lower back, upper arm or chest, in a place which will not be rubbed by tight clothing.
KVALITATIV OG KVANTITATIV SAMMENSÆTNING Hvert depotplaster frigiver 9,5 mg rivastigmin pr. 24 timer. 
QUALITATIVE AND QUANTITATIVE COMPOSITION Each transdermal patch releases 9.5 mg of rivastigmine per 24 hours.
Almindelig (kan forekomme hos op til 1 ud af 10 patienter) - Appetitløshed - Svimmelhed - Træthed- eller svaghedsfornemmelse - Urininkontinens (manglende evne til at holde på urinen) 
Common (may affect up to 1 in 10 people) - Loss of appetite - Feeling dizzy - Feeling agitated or sleepy - Urinary incontinence (inability to retain adequate urine)
Ellers vil din læge genstarte din behandling med Rivastigmine 3M Health Care Ltd. 4,6 mg/24 timer. 
Otherwise your doctor will restart your treatment on Rivastigmine 3M Health Care Ltd. 4.6 mg/24 h.
Kvalme, opkastning, diarré, dyspepsi, mavesmerter 
Nausea, vomiting, diarrhoea, dyspepsia, abdominal pain
KVALITATIV OG KVANTITATIV SAMMENSÆTNING Hvert depotplaster frigiver 4,6 mg rivastigmin pr. 24 timer. 
QUALITATIVE AND QUANTITATIVE COMPOSITION Each transdermal patch releases 4.6 mg of rivastigmine per 24 hours.
Der er ikke udført specifikke interaktionsstudier med Rivastigmine 3M Health Care Ltd. depotplastre. 
No specific interaction studies have been performed with Rivastigmine 3M Health Care Ltd. transdermal patches.
Transdermal anvendelse 
Transdermal use
I forhold til plasmakoncentrationen over 24 timer, kan der ikke direkte sættes lighedstegn mellem dosen af rivastigmin frigivet fra depotplastret over 24 timer (mg/24 timer) og mængden (mg) rivastigmin en kapsel indeholder. 
The dose of rivastigmine released from the transdermal patch over 24 hours (mg/24 h) cannot be directly equated to the amount (mg) of rivastigmine contained in a capsule with respect to plasma concentration produced over 24 hours.
Meget sjælden (kan forekomme hos op til 1 ud af 10.000 patienter) Stivhed i arme eller ben 
Very rare (may affect up to 1 in 10,000 people) - Stiff arms or legs - Trembling hands
Indberetning af mistænkte bivirkninger 
Reporting of suspected adverse reactions
I tilfælde af, at limrester er tilovers på din hud, opblød forsigtigt området med varmt vand og mild sæbe eller brug babyolie til at fjerne det. 
In case the adhesive residue is left over on your skin, gently soak the area with warm water and mild soap or use baby oil to remove it. Alcohol or other dissolving liquids (nail polish remover or other solvents) should not be used.
Graviditet, amning og frugtbarhed 
Pregnancy, breast feeding and fertility
Rivastigmin udskilles i mælken hos dyr. 
In animals, rivastigmine is excreted into milk.
• Nedsat nyrefunktion: Dosisjustering er ikke nødvendig hos patienter med nedsat nyrefunktion. 
- Renal impairment: No dose adjustment is necessary for patients with renal impairment.
Opbevares i originalemballagen for at beskytte mod lys. 
Store in the original package in order to protect from light.
Denne indlægsseddel blev senest ændret <{MM/ÅÅÅÅ}> 
This leaflet was last revised in {month YYYY}
Initialdosis Behandlingen indledes med 4,6 mg/24 timer. 
Initial dose Treatment is started with 4.6 mg/24 h.
Hvis der observeres gastrointestinale bivirkninger, bør behandlingen afbrydes midlertidigt, indtil bivirkningerne er ophørt. 
Treatment should be temporarily interrupted if gastrointestinal adverse reactions are observed until these adverse reactions resolve.
Efter at have skiftet til 4,6 mg/24 timer depotplastre, bør dosis på 4,6 mg/24 timer, forudsat at denne er veltolereret efter minimum 4 ugers behandling, øges til 9,5 mg/24 timer, som er den anbefalede effektive dosis. 
After switching to 4.6 mg/24 h transdermal patches, provided these are well tolerated after a minimum of four weeks of treatment, the dose of 4.6 mg/24 h should be increased to 9.5 mg/24 h, which is the recommended effective dose.
- Opbevar dette lægemiddel utilgængeligt for børn. 
- Keep this medicine out of the sight and reach of children.
Patienterne og deres omsorgspersoner skal instrueres i vigtige administrationsinstruktioner for Rivastigmine 3M Health Care Ltd. depotplaster (se pkt. 
Patients and their caregivers must be instructed on important administration instructions for Rivastigmine 3M Health Care Ltd. transdermal patch (see section 4.2).
Sådan tager du dit Rivastigmine 3M Health Care Ltd. depotplaster af Træk forsigtigt i kanten af plasteret for at fjerne det langsomt helt fra huden. 
How to remove your Rivastigmine 3M Health Care Ltd. transdermal patch Gently pull at one edge of the patch to remove it slowly from the skin.
Leversygdomme (gulfarvet hud, gulfarvning af det hvide i øjnene, unormalt mørk urin eller uforklarlig kvalme, opkastning, træthed eller appettitløshed) Ændringer i tests, som viser hvor godt leveren fungerer 
- Fast or uneven heartbeat - High blood pressure - Fits (seizures) - Liver disorders (yellow skin, yellowing of the whites of the eyes, abnormal darkening of the urine or unexplained nausea, vomiting, tiredness and loss of appetite) - Changes in tests which show how well the liver is working - Feeling restless
- Klip ikke plasteret i stykker. 
- Do not cut the patch into pieces.
Sådan sætter du dit Rivastigmine 3M Health Care Ltd. depotplaster på Rivastigmine 3M Health Care Ltd. depotplastre er tynde, uigennemsigtigte plast-plastre, som klæber til huden. 
How to apply your Rivastigmine 3M Health Care Ltd. transdermal patch Rivastigmine 3M Health Care Ltd. patches are transparent to translucent, plastic patches that stick to the skin.
På grund af øget biotilgængelighed hos disse patienter observeret med de orale formuleringer, bør anbefalingerne vedrørende titrering i henhold til individuel tolerance dog følges nøje, da patienter med klinisk signifikant nedsat nyrefunktion kan opleve flere bivirkninger (se pkt. 
However, due to increased exposure in these populations as observed with the oral forms, dosing recommendations to titrate according to individual tolerability should be closely followed as patients with clinically significant renal impairment might experience more adverse reactions (see sections 4.4 and 5.2).
UDLØBSDATO Udløbsdato 
EXPIRY DATE
Renal udskillelse af metabolitterne er den væsentligste udskillelsesvej efter administration af depotplaster. 
Unchanged rivastigmine is found in trace amounts in the urine; renal excretion of the metabolites is the major route of elimination after transdermal patch administration.
Patienter med stærkt nedsat leverfunktion er ikke blevet undersøgt (se pkt. 
Patients with severe hepatic impairment have not been studied (see sections 4.4 and 5.2).
Det aktive lægemiddel i Rivastigmine 3M Health Care Ltd. er rivastigmin. 
The active substance of Rivastigmine 3M Health Care Ltd. is rivastigmine.
ANGIVELSE AF AKTIVT STOF/AKTIVE STOFFER 1 depotplaster på 4,15 cm2 indeholder 7,17 mg rivastigmin og afgiver 4,6 mg/24 timer. 
STATEMENT OF ACTIVE SUBSTANCE(S) 1 transdermal patch of 4.15 cm2 contains 7.17 mg rivastigmine and delivers 4.6 mg/24 h.
Patientens vægt bør overvåges under behandling med Rivastigmine 3M Health Care Ltd. depotplastre. 
The patient's weight should be monitored during therapy with Rivastigmine 3M Health Care Ltd. transdermal patches.
• Patienter med en legemsvægt på under 50 kg kan opleve flere bivirkninger og har større risiko for at måtte afbryde behandlingen på grund af bivirkninger (se pkt. 
Special populations: - Patients with body weight below 50 kg may experience more adverse reactions and may be more likely to discontinue due to adverse reactions (see section 4.2).
DLSM 95% CI p-værdi 
Rivastigmine 9.5 mg/24 h n Mean n Mean DLSM 95% CI p-value
M/P-ratio for AUC∞ var omkring 0,7 efter depotplaster administration mod 3,5 efter oral administration. 
The metabolite-to-parent AUC∞ ratio was around 0.7 after transdermal patch administration versus 3.5 after oral administration, indicating that much less metabolism occurred after dermal compared to oral treatment.
Hvis du skal opereres, mens du er i behandling med Rivastigmine 3M Health Care Ltd. depotplastre, skal du fortælle det til din læge, da Rivastigmine 3M Health Care Ltd. kan forstærke effekten af muskelafslappende midler under bedøvelse. 
If you have to undergo surgery whilst using Rivastigmine 3M Health Care Ltd. transdermal patches, tell your doctor that you are using them because they may exaggerate the effects of some muscle relaxants during anaesthesia.
Hudreaktioner på applikationsstedet (f.eks. erytem på applikationsstedet, kløe ved applikationsstedet, ødem ved applikationsstedet, dermatitis på applikationsstedet, irritation ved applikationsstedet), asteniske lidelser (f.eks. træthed, asteni), pyreksi, vægttab 
Application site skin reactions (e.g. application site erythema, application site pruritus, application site oedema, application site dermatitis, application site irritation), asthenic conditions (e.g. fatigue,
- Rivastigmine 3M Health Care Ltd. 4,6 mg/24 timer depotplaster: Hvert depotplaster frigiver 4,6 mg rivastigmin pr. 24 timer, er 4,15 cm2 og indeholder 7,17 mg rivastigmin. 
- Rivastigmine 3M Health Care Ltd. 4.6 mg/24 h transdermal patches: Each patch releases 4.6 mg of rivastigmine per 24 hours, is 4.15 cm2 and contains 7.17 mg of rivastigmine.
Eksponeringen for rivastigmin (Cmax og AUC) steg overproportionalt med en faktor på 2,6 og 4,9 ved skift fra 4,6 mg/24 timer til henholdsvis 9,5 mg/24 timer og til 13,3 mg/24 timer, hvilket er mindre udtalt end ved den orale formulering. 
Although less pronounced than with the oral formulation, exposure to rivastigmine (Cmax and AUC) increased over-proportionally by a factor of 2.6 and 4.9 when escalating from 4.6 mg/24 h to 9.5 mg/24 h and to 13.3 mg/24 h, respectively.
De hyppigst rapporterede hændelser med hudirritationer i løbet af de første 24 uger af den dobbeltblindede periode med rivastigmin 13,3 mg/24 timer depotplastre og rivastigmin 9,5 mg/24 timer depotplastre, var henholdsvis erytem på applikationsstedet (5,7% mod 4,6%) og kløe på applikationsstedet (3,6% mod 2,8%). 
The most commonly reported skin irritation events during the first 24 weeks of the double-blind period with rivastigmine 13.3 mg/24 h transdermal patches and rivastigmine 9.5 mg/24 h transdermal patches, respectively were application site erythema (5.7% vs 4.6%) and application site pruritus (3.6% vs 2.8%).
LISTE OVER HJÆLPESTOFFER Indeholder også polyester, ethylvinylacetat, acrylatcopolymerklæbemiddel og isopropylmyristat. 
LIST OF EXCIPIENTS Also contains polyester, ethyl vinyl acetate, acrylate copolymer adhesive and isopropyl myristate.
Dæklag: -Polyester 
Polyester
Eksempler på disse lægemidler er: antacida, antiemetika, antidiabetika, centralt virkende antihypertensiva, betablokkere, calciumkanalblokkere, inotrope midler, midler mod angina pectoris, non-steroide antiinflammatoriske stoffer, østrogener, analgetika, benzodiazepiner og antihistaminer. 
Concomitant administration of rivastigmine with commonly prescribed medicinal products, such as antacids, antiemetics, antidiabetics, centrally acting antihypertensives, beta blockers, calcium channel blockers, inotropic agents, antianginals, non-steroidal anti-inflammatory agents, oestrogens, analgesics, benzodiazepines and antihistamines, was not associated with an alteration in the kinetics of rivastigmine or an increased risk of clinically relevant untoward effects.
For at mindske risikoen for hudirritation bør der gå mindst 14 dage mellem, at plasteret påføres samme sted på huden. 
Reapplication to the exact same skin location within 14 days should be avoided to minimise the potential risk of skin irritation.
Efter mindst fire ugers behandling, og hvis denne dosis ifølge den behandlende læge tåles godt, bør dosis med 4,6 mg/24 timer øges til 9,5 mg/24 timer, som er den anbefalede virksomme dosis, anvendes så længe der er terapeutisk effekt for patienten. 
After a minimum of four weeks of treatment and if well tolerated according to the treating physician, the dose of 4.6 mg/24 h should be increased to 9.5 mg/24 h, the daily recommended effective dose, which should be continued for as long as the patient continues to demonstrate therapeutic benefit.
- Hvis plasteret faller af, skal et nyt plaster påføres for resten af dagen. 
- If the patch falls off, a new one should be applied for the rest of the day, then it should be replaced at the same time as usual the next day.
Rivastigmine 3M Health Care Ltd. udseende og pakningsstørrelser Depotplastrene er rektangulære med afrundede hjørner, plastre, cirka 2,5 cm x 1,8 cm Rivastigmine 3M Health Care Ltd. 4,6 mg/24 timer depotplaster) eller 3,5 cm x 2,6 cm (Rivastigmine 3M Health Care Ltd. 9,5 mg/24 timer depotplaster). 
What Rivastigmine 3M Health Care Ltd. looks like and contents of the pack The transdermal patches are rectangular with rounded corners, approximately 2.5 cm by 1.8 cm (Rivastigmine 3M Health Care Ltd. 4.6 mg/24 h transdermal patch) or 3.5 cm by 2.6 cm (Rivastigmine 3M Health Care Ltd. 9.5 mg/24 h transdermal patch).
- Tryk herefter plastret godt fast i mindst 30 sekunder ved hjælp af håndfladen for at sikre, at hjørnerne sidder fast. 
- Then press the patch firmly in place for at least 30 seconds using the palm of the hand to make sure that the edges stick well.
- Rivastigmine 3M Health Care Ltd. 9,5 mg/24 timer depotplaster: Hvert depotplaster frigiver 9,5 mg rivastigmin pr. 24 timer, er 8,3 cm2 og indeholder 14,33mg rivastigmin. 
- Rivastigmine 3M Health Care Ltd. 9.5 mg/24 h transdermal patches: Each patch releases 9.5 mg of rivastigmine per 24 hours, is 8.3 cm2 and contains 14.33 mg of rivastigmine.
BETINGELSER ELLER BEGRÆNSNINGER MED HENSYN TIL SIKKER OG 
CONDITIONS OR RESTRICTIONS REGARDING SUPPLY
Der var ingen relevant akkumulering af rivastigmin eller metabolitten NAP226-90 i plasma hos patienter med Alzheimers demens. 
There was no relevant accumulation of rivastigmine or the metabolite NAP226-90 in plasma in patients with Alzheimer's disease, except that plasma levels were higher on the second day of transdermal patch therapy than on the first.
Procentdelen faldt hos behandlingsgruppen over tid (>24 uger) med både rivastigmin 13,3 mg/24 timer depotplaster og rivastigmin 9,5 mg/24 timer depotplaster: Henholdsvis erytem på applikationsstedet (0,8% mod 1,6%) og kløe på applikationsstedet (0,4% mod 1,2%). 
The percentages decreased in both rivastigmine 13.3 mg/24 h transdermal patch and rivastigmine 9.5 mg/24 h transdermal patch treatment groups over time (>24 weeks): application site erythema (0.8% vs. 1.6%) and application site pruritus (0.4% vs. 1.2%), respectively.
- Øvrige indholdsstoffer polyester, ethylvinylacetat, acrylatcopolymerklæbemiddel og isopropylmyristat. 
- The other ingredients are polyester, ethyl vinyl acetate, acrylate copolymer adhesive and isopropyl myristate.
Lever og galdeveje Hud og subkutane væv 
Hepatitis, elevated liver function tests Skin and subcutaneous tissue disorders Common Not known
Kendt overfølsomhed over for det aktive stof rivastigmin, over for andre carbamatderivater eller over for et eller flere af hjælpestofferne anført i pkt. 
The use of this medicinal product is contraindicated in patients with known hypersensitivity to the active substance rivastigmine, to other carbamate derivatives or to any of the excipients listed in section 6.1.
Nervesystemet 
Nervous system disorders Common
- Brug kun ét plaster ad gangen og udskift plasteret med et nyt efter 24 timer. 
- Only wear one Rivastigmine 3M Health Care Ltd. patch at a time and replace the patch with a new one after 24 hours.
Hvis du har glemt at bruge Rivastigmine 3M Health Care Ltd. 
If you forget to use Rivastigmine 3M Health Care Ltd.
• Klip ikke plasteret i stykker. 
• Do not cut the patch into pieces.
Nedsat leverfunktion 
Weight loss
Ændring 264 4,1 268 4,9 -0,8 (-2,1, 0,5) 0,227 
DB-week 48 Value Change 264 4.1 268 4.9 -0.8 (-2.1,
Der er ingen relevante indikationer for brug af Rivastigmine 3M Health Care Ltd. til behandling af Alzheimers sygdom hos børn og teenagere. 
There is no relevant use of Rivastigmine 3M Health Care Ltd. in the paediatric population in the treatment of Alzheimer's disease.
• En patient, som får en dosis på 6 mg/dag oral rivastigmin, kan skiftes til 4,6 mg/24 timer depotplastre. 
- A patient on a dose of 6 mg/day oral rivastigmine can be switched to 4.6 mg/24 h transdermal patches.
- Plasteret trykkes godt ned i mindst 30 sekunder med håndfladen , indtil kanterne sidder godt fast. 
- The patch should be pressed down firmly for at least 30 seconds using the palm of the hand until the edges stick well.
Bagsidelaget er gennemsigtigt til gennemskinneligt og mærket med "R5" (Rivastigmine 3M Health Care Ltd. 4,6 mg/24 timer depotplaster) eller 3,5 cm x 2,6 cm (Rivastigmine 3M Health Care Ltd. 9,5 mg/24 timer depotplaster). 
The backing layer is transparent to translucent and labelled with “R5” (Rivastigmine 3M Health Care Ltd. 4.6 mg/24 h transdermal patch) or “R10” (Rivastigmine 3M Health Care Ltd. 9.5 mg/24 h transdermal patch).